Cytokinetics, Incorporated (CYTK) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $63.22 (-0.31%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Roanna Ruiz | Robert W. Baird | $84.00 | +32.9% |
| Mar 6, 2026 | Ashwani Verma | UBS | $69.00 | +9.1% |
| Feb 3, 2026 | Srikripa Devarakonda | Truist Financial | $92.00 | +45.5% |
| Jan 9, 2026 | Akash Tewari | Jefferies | $90.00 | +42.4% |
| Jan 8, 2026 | Maxwell Skor | Morgan Stanley | $90.00 | +42.4% |
| Dec 22, 2025 | Srikripa Devarakonda | Truist Financial | $84.00 | +32.9% |
| Dec 22, 2025 | Roanna Ruiz | Leerink Partners | $83.00 | +31.3% |
| Dec 22, 2025 | Serge Belanger | Needham | $84.00 | +32.9% |
| Dec 22, 2025 | Joseph Pantginis | H.C. Wainwright | $136.00 | +115.1% |
| Dec 1, 2025 | Ashwani Verma | UBS | $61.00 | -3.5% |
| Oct 6, 2025 | Gena Wang | Barclays | $82.00 | +29.7% |
| Sep 3, 2025 | Cory Kasimov | Evercore ISI | $80.00 | +26.5% |
| Sep 3, 2025 | Gena Wang | Barclays | $71.00 | +12.3% |
| Sep 2, 2025 | James Condulis | Stifel Nicolaus | $96.00 | +51.9% |
| Apr 24, 2025 | Gena Wang | Barclays | $55.00 | -13.0% |
| Oct 17, 2024 | Joseph Pantginis | H.C. Wainwright | $120.00 | +89.8% |
| Sep 3, 2024 | Paul Choi | Goldman Sachs | $60.00 | -5.1% |
| Jun 10, 2024 | Yasmeen Rahimi | Piper Sandler | $107.00 | +69.3% |
| Jun 4, 2024 | Mayank Mamtani | B.Riley Financial | $92.00 | +45.5% |
| May 28, 2024 | Jason Butler | JMP Securities | $78.00 | +23.4% |
Top Analysts Covering CYTK
CYTK vs Sector & Market
| Metric | CYTK | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 20 | 8 | 19 |
| Target Upside | +79.3% | +153002.0% | +21.5% |
| P/E Ratio | -9.43 | 3.48 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $58M | $92M | $177M | 15 |
| 2027-03-31 | $27M | $56M | $97M | 6 |
| 2027-06-30 | $38M | $80M | $140M | 6 |
| 2027-09-30 | $52M | $108M | $188M | 6 |
| 2027-12-31 | $74M | $155M | $269M | 6 |
| 2028-03-31 | $17M | $35M | $61M | 6 |
| 2028-06-30 | $18M | $38M | $66M | 5 |
| 2028-09-30 | $20M | $41M | $71M | 5 |
| 2028-12-31 | $21M | $44M | $77M | 6 |
| 2029-12-31 | $1.18B | $1.45B | $2.09B | 9 |
| 2030-12-31 | $1.81B | $2.21B | $3.19B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-7.56 | $-6.50 | $-4.61 | 15 |
| 2027-03-31 | $-2.99 | $-1.52 | $-0.49 | 4 |
| 2027-06-30 | $-2.66 | $-1.35 | $-0.44 | 4 |
| 2027-09-30 | $-2.36 | $-1.21 | $-0.39 | 4 |
| 2027-12-31 | $-1.73 | $-0.89 | $-0.29 | 4 |
| 2028-03-31 | $-2.67 | $-1.36 | $-0.44 | 5 |
| 2028-06-30 | $-2.20 | $-1.12 | $-0.36 | 5 |
| 2028-09-30 | $-5.00 | $-2.55 | $-0.82 | 5 |
| 2028-12-31 | $-1.28 | $-0.65 | $-0.21 | 5 |
| 2029-12-31 | $0.50 | $0.66 | $1.04 | 8 |
| 2030-12-31 | $3.08 | $4.04 | $6.38 | 12 |
Frequently Asked Questions
What is the analyst consensus for CYTK?
The consensus among 20 analysts covering Cytokinetics, Incorporated (CYTK) is Buy with an average price target of $112.50.
What is the highest price target for CYTK?
The highest price target for CYTK is $136.00, set by Joseph Pantginis at H.C. Wainwright on 2025-12-22.
What is the lowest price target for CYTK?
The lowest price target for CYTK is $45.00, set by Jeffrey Hung at Morgan Stanley on 2021-10-08.
How many analysts cover CYTK?
20 analysts have issued ratings for Cytokinetics, Incorporated in the past 12 months.
Is CYTK a buy or sell right now?
Based on 20 analyst ratings, CYTK has a consensus rating of Buy (2.00/5) with a +79.3% upside to the consensus target of $112.50.
What are the earnings estimates for CYTK?
Analysts estimate CYTK will report EPS of $-6.50 for the period ending 2026-12-31, with revenue estimated at $92M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.